Toshio Takagi

6.5k total citations
275 papers, 3.2k citations indexed

About

Toshio Takagi is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Toshio Takagi has authored 275 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 207 papers in Pulmonary and Respiratory Medicine, 103 papers in Surgery and 94 papers in Oncology. Recurrent topics in Toshio Takagi's work include Renal cell carcinoma treatment (191 papers), Bladder and Urothelial Cancer Treatments (80 papers) and Renal and related cancers (78 papers). Toshio Takagi is often cited by papers focused on Renal cell carcinoma treatment (191 papers), Bladder and Urothelial Cancer Treatments (80 papers) and Renal and related cancers (78 papers). Toshio Takagi collaborates with scholars based in Japan, United States and Italy. Toshio Takagi's co-authors include Kazunari Tanabe, Kazuhiko Yoshida, Junpei Iizuka, Tsunenori Kondo, Hirohito Kobayashi, Hiroki Ishihara, Steven C. Campbell, Kenji Omae, Sevag Demirjian and Tsunenori Kondo and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Toshio Takagi

246 papers receiving 3.2k citations

Peers

Countries citing papers authored by Toshio Takagi

Since Specialization

Citations

This map shows the geographic impact of Toshio Takagi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toshio Takagi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toshio Takagi more than expected).

Fields of papers citing papers by Toshio Takagi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Toshio Takagi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toshio Takagi. The network helps show where Toshio Takagi may publish in the future.

Co-authorship network of co-authors of Toshio Takagi

This figure shows the co-authorship network connecting the top 25 collaborators of Toshio Takagi. A scholar is included among the top collaborators of Toshio Takagi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Toshio Takagi. Toshio Takagi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Release of apoptosis inhibitor of macrophage (AIM) from pentameric IgM in serum predicts prognosis after hemodialysis initiation 2025 ·Communications Medicine ·(unknown), (unknown), Tomoko Inoue, Toshio Takagi, Kazunari Tanabe, Jun Minakuchi, Satoko Arai, Toru Miyazaki	0
2	Efficacy of robot-assisted partial nephrectomy compared to conventional laparoscopic partial nephrectomy for completely endophytic renal tumor: a multicenter, prospective study 2024 ·International Journal of Clinical Oncology ·Nobuyuki Hinata, (unknown), Yuzo Nakano, Isao Hara, Tsunenori Kondo, Shuzo Hamamoto, Ryoichi Shiroki, (unknown), Mutsushi Kawakita, (unknown), Osamu Ukimura, Atsushi Takenaka, Toshio Takagi, Masaki Shimbo, Haruhito Azuma, Tetsuya Yoshida, Junya Furukawa, Naoki Kawamorita, Masato Fujisawa	1
3	Tips for percutaneous nephrolithotomy for transplant kidney stone 2024 ·IJU Case Reports ·T Yagisawa, Tomokazu Shimizu, (unknown), (unknown), (unknown), Shoichi Iida, Hideki Ishida, Toshio Takagi	0
4	Real-world outcomes of nivolumab plus ipilimumab combination therapy for advanced renal cell carcinoma in Japanese patients: data with a minimum of 3 years of follow-up 2024 ·Japanese Journal of Clinical Oncology ·Hiroki Ishihara, (unknown), (unknown), Takashi Ikeda, (unknown), Hironori Fukuda, Kazuhiko Yoshida, Hiroaki Shimmura, Yasunobu Hashimoto, Junpei Iizuka, Tsunenori Kondo, Toshio Takagi	4
5	First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data 2024 ·International Journal of Clinical Oncology ·Hiroki Ishihara, Kenji Omae, (unknown), (unknown), Hidekazu Tachibana, Koichi Nishimura, Takashi Ikeda, (unknown), Hironori Fukuda, Kazuhiko Yoshida, Hiroaki Shimmura, Yasunobu Hashimoto, Junpei Iizuka, Tsunenori Kondo, Toshio Takagi	7
6	A retrospective cohort study of the impact of peripheral blood gamma- delta T cells to prognosis of nonmetastatic renal cell cancer after curative resection 2023 ·Urologic Oncology Seminars and Original Investigations ·Hirohito Kobayashi, Tsunenori Kondo, Junpei Iizuka, Kazuhiko Yoshida, Toshio Takagi	0
7	En bloc kidney transplantation from pediatric donors to teenage recipients: Two case reports 2023 ·IJU Case Reports ·T Yagisawa, (unknown), Toshihito Hirai, Kohei Unagami, Yoko Shirai, Kiyonobu Ishizuka, Kenichiro Miura, (unknown), Hideki Ishida, Toshio Takagi	0
8	Case Report: Suspected Hyperacute Rejection During Living Kidney Transplantation 2023 ·Transplantation Proceedings ·Tomokazu Shimizu, Shoichi Iida, Kazuya Omoto, Masashi Inui, Taiji Nozaki, Hiroshi Toma, Toshio Takagi, Hideki Ishida	0
9	Long-time Survival of a Renal Transplant Recipient With Metastatic Mucinous Tubular and Spindle Cell Carcinoma: A Case Report 2023 ·In Vivo ·(unknown), Kazuhiko Yoshida, (unknown), Hironori Fukuda, Keisuke Hata, Kohei Unagami, Junpei Iizuka, Hideki Ishida, Yoji Nagashima, Toshio Takagi	3
10	Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors 2023 ·Japanese Journal of Clinical Oncology ·(unknown), Hiroki Ishihara, Kazutaka Nakamura, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, (unknown), Hiroaki Shimmura, Yasunobu Hashimoto, (unknown), Toshio Takagi	5
11	Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study 2023 ·Targeted Oncology ·Hiroki Ishihara, (unknown), Kazutaka Nakamura, Hidekazu Tachibana, Takashi Ikeda, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Tsunenori Kondo, Toshio Takagi	10
12	Real-world efficacy and safety of cabozantinib following immune checkpoint inhibitor failure in Japanese patients with advanced renal cell carcinoma 2023 ·Japanese Journal of Clinical Oncology ·Hiroki Ishihara, (unknown), Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Yasunobu Hashimoto, Tsunenori Kondo, Toshio Takagi	1
13	Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era 2022 ·Targeted Oncology ·Hiroki Ishihara, (unknown), Kazutaka Nakamura, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Kazunari Tanabe, Tsunenori Kondo, Toshio Takagi	7
14	Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy for Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria 2022 ·Targeted Oncology ·(unknown), Hiroki Ishihara, Kazutaka Nakamura, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Kazunari Tanabe, Tsunenori Kondo, Toshio Takagi	3
15	Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era 2020 ·Urologic Oncology Seminars and Original Investigations ·Toshio Takagi, Hironori Fukuda, Hiroki Ishihara, Kazuhiko Yoshida, Tsunenori Kondo, Hirohito Kobayashi, Junpei Iizuka, Masayoshi Okumi, Hideki Ishida, Kenji Omae, Kazunari Tanabe	14
16	Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma 2019 ·International Journal of Clinical Oncology ·Hiroki Ishihara, Toshio Takagi, Tsunenori Kondo, Hironori Fukuda, Hidekazu Tachibana, Kazuhiko Yoshida, Junpei Iizuka, Hirohito Kobayashi, Masayoshi Okumi, Hideki Ishida, Kazunari Tanabe	5
17	Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy 2019 ·Japanese Journal of Clinical Oncology ·Kazuhiko Yoshida, Toshio Takagi, Tsunenori Kondo, Hirohito Kobayashi, Junpei Iizuka, Hironori Fukuda, Hiroki Ishihara, Masayoshi Okumi, Hideki Ishida, Kazunari Tanabe	12
18	Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab 2019 ·Urologic Oncology Seminars and Original Investigations ·Hiroki Ishihara, Toshio Takagi, Tsunenori Kondo, (unknown), Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Junpei Iizuka, Hirohito Kobayashi, Masayoshi Okumi, Hideki Ishida, Kazunari Tanabe	81
19	Decreased relative dose intensity during the early phase of treatment impacts the therapeutic efficacy of sunitinib in metastatic renal cell carcinoma 2018 ·Japanese Journal of Clinical Oncology ·Hiroki Ishihara, Toshio Takagi, Tsunenori Kondo, (unknown), Hidekazu Tachibana, Kazuhiko Yoshida, Kenji Omae, Junpei Iizuka, Hirohito Kobayashi, Kazunari Tanabe	14
20	Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma 2018 ·Targeted Oncology ·Hiroki Ishihara, Toshio Takagi, Tsunenori Kondo, Hironori Fukuda, Kazuhiko Yoshida, Junpei Iizuka, Kazunari Tanabe	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact